Biocon Limited (NSE: BIOCON)

India flag India · Delayed Price · Currency is INR
352.80
-3.90 (-1.09%)
Dec 13, 2024, 3:30 PM IST
47.83%
Market Cap 422.23B
Revenue (ttm) 148.94B
Net Income (ttm) 14.39B
Shares Out 1.20B
EPS (ttm) 12.00
PE Ratio 29.40
Forward PE 49.18
Dividend 0.50 (0.14%)
Ex-Dividend Date Jul 5, 2024
Volume 2,637,696
Open 356.00
Previous Close 356.70
Day's Range 346.75 - 356.80
52-Week Range 239.30 - 395.80
Beta 0.45
Analysts n/a
Price Target n/a
Earnings Date Jan 29, 2025

About Biocon

Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1978
Employees 16,315
Stock Exchange National Stock Exchange of India
Ticker Symbol BIOCON
Full Company Profile

Financial Performance

In 2023, Biocon's revenue was 147.56 billion, an increase of 32.05% compared to the previous year's 111.74 billion. Earnings were 10.23 billion, an increase of 120.99%.

Financial Statements

News

Pharma stocks: Divi’s Lab (+0.82%), IPCA (+0.83%) rise; Biocon (-1.86%), Glaxo (-1.44%) decline

The pharma sector showed a mixed trend during intraday trading as of 11:25 AM, with select stocks gaining while others faced selling pressure. Key Performances: Gaining Stocks: IPCA Laboratories: Up 0...

2 days ago - Business Upturn

Pharma Stocks: Cipla down nearly 2%, Ajanta Pharma down 1.45%, Abbott India up 1.27%

The Nifty Pharma index was trading 0.25% lower at 22,389.10 during today’s session, as losses in Cipla, Biocon, and Aurobindo Pharma weighed on the sector, despite gains in Abbott India and Ajanta Pha...

10 days ago - Business Upturn

Biocon shares surge nearly 3% after FDA nod for Yesintek, a biosimilar to Stelara

Shares of Biocon surged by 2.7% to Rs 375 on Monday following the U.S. FDA’s approval for Yesintek, a biosimilar to Johnson & Johnson’s blockbuster arthritis drug, Stelara. This approval marks a signi...

12 days ago - Business Upturn

Stocks to watch today: Maruti Suzuki, TVS Motor, Biocon, DLF, RVNL, RBL, Cipla, Home First, Cochin Shipyard in focus

The stock market is abuzz with updates across several companies today. Below are the highlights in the green and red zones: Maruti Suzuki: November sales saw a minor beat, driven by a strong performan...

12 days ago - Business Upturn

Pharma stocks weekly roundup: Biocon leads with 9.08% gain, Torrent Pharma up 4.91%, Lupin dips 1.82%

The pharmaceutical sector experienced diverse movements during the week of November 25–29, 2024. Among the notable performers, Biocon Ltd led the gains with a significant surge of ₹30.35 (9.08%), clos...

13 days ago - Business Upturn

Biocon shares surge over 3% after Bengaluru facilities get VAI Tag from USFDA

Biocon Ltd. saw its shares rise by more than 3% in early trading after the U.S. Food and Drug Administration (USFDA) issued a “Voluntary Action Indicated” (VAI) tag to the manufacturing facilities of ...

4 weeks ago - Business Upturn

Stocks to watch today: Divi’s Laboratories, JSW Steel, LIC, Biocon in focus; Asian Paints, Tata Motors, Aurobindo Pharma, Ola Electric under pressure

In today’s market action, key stocks to watch include Divi’s Laboratories, which reported better-than-expected results, and JSW Steel, which has been chosen as the preferred bidder for new coal blocks...

4 weeks ago - Business Upturn

Access to healthcare will remain a priority for the US, says Biocon CEO

Peter Bains, Group CEO of Biocon, talks about how the India-based pharmaceutical company is placed ahead of a second Trump presidency, as well as the development of its weight-loss and anti-obesity dr...

5 weeks ago - CNBC

Pharma Sector Stocks: Granules down 1.68%, Akums slips 1.29%, Zydus Life up 0.13%, Aurobindo Pharma gains 0.99% in early trade

Time Stamp: November 4, 2024, 9:41 AM Market Update: Pharma stocks opened with a mixed trend today, showing slight gains and losses among the major players. SPARC: Down by 1.81%, trading at ₹212.04 PP...

5 weeks ago - Business Upturn

Stocks to watch today: L&T, Voltas, Dabur, Aditya Birla Capital, Tata Power, and Biocon post Q2 results – Brokerage reports inside

Several leading companies, including Larsen & Toubro (L&T), Voltas, Dabur, Aditya Birla Capital, Tata Power, and Biocon, announced their Q2 FY25 results yesterday. Here’s a look at their performance, ...

6 weeks ago - Business Upturn

Biocon Q2 FY25 Results: Company posts net loss of Rs 16 crore, Revenue flat at Rs 3,623 crore

Biocon reported a net loss of ₹16 crore for the period, attributed to higher tax expenses resulting from a geographical shift in profits and minority interest.

6 weeks ago - Business Upturn

Stocks to watch today as key Q2 FY24-25 results roll in: L&T, Tata Power, Dabur, PGHH, Biocon, Aditya Birla Capital and more

Today is set to be an active trading day with several prominent companies scheduled to release their Q2 FY24-25 earnings. Investors will be closely analyzing these results to gauge company performance...

6 weeks ago - Business Upturn

HSBC on Biocon: Reduce call, sees 7.8% downside from current share price

HSBC has maintained its reduce rating on Biocon, lowering the share price target to ₹300, implying a 7.8% downside from the current market price (CMP). A positive court ruling positions Amgen well for...

7 weeks ago - Business Upturn

Pharma Stocks Update: Check out how Cipla, Lupin, Abbott India, Divi’s Lab, Zydus Life, Dr Reddy’s Lab are performing today

JB Chem rises 1.91%, Biocon gains 0.87%, while Natco Pharma drops 2.65% and Gland Pharma slips 1.38% in today's trade.

2 months ago - Business Upturn

Biocon’s subsidiary refinances USD 1.1 Billion long-term debt through USD bonds and new syndicated facility

Biocon Biologics Limited (BBL), a subsidiary of Biocon Limited, successfully refinanced its USD 1.1 billion (INR 93,468 million) long-term debt through the issuance of USD 800 million (INR 66,763 mill...

2 months ago - Business Upturn

Stock Market 14 Feb, Today: Focus on new listings, 3 IPOs to track today

Today’s stock market highlights several companies experiencing key developments, with notable movements in IT, renewable energy, pharma, and finance sectors. Accenture’s positive revenue guidance has ...

2 months ago - Business Upturn

Biocon Limited partners with Tabuk Pharmaceuticals

To commercialise its Glucagon-like peptide-1 (GLP -1) products in the Middle East region

2 months ago - Zawya

Biocon and Tabuk Pharmaceuticals join forces to commercialize GLP-1 products in Middle East markets

Biocon Limited has recently informed exchanges that the company has signed a licensing and supply agreement with Tabuk Pharmaceutical Manufacturing Company (a fully-owned subsidiary of Astra Industria...

2 months ago - Business Upturn

F&O ban update: ABFRL, IDEA enter ban; RBL Bank exits on Sept 24

In today’s stock market session, several changes were observed in the Futures and Options (F&O) ban list. New additions to the ban: ABFRL and IDEA have been placed under the F&O ban. These stocks have...

2 months ago - Business Upturn

Stock market news: Aarti Industries, Biocon, GNFC, Granules India among stocks in F&O ban list on September 20

Several stocks remain in the Futures and Options (F&O) ban period as their open interest (OI) has crossed 95% of the market-wide position limits (MWPL). These stocks will remain in the ban until their...

2 months ago - Business Upturn

LIC increases its stake in Biocon to 5.03%

The Life Insurance Corporation of India (LIC) has announced an increase in its equity shareholding in Biocon Ltd

3 months ago - Business Upturn

Biocon Biologics set to raise $950 million through overseas bonds

Biocon Biologics is planning to raise $950 million by selling bonds overseas, according to reports of Economic Times. The fundraising will be handled by lenders including Standard Chartered Bank and H...

3 months ago - Business Upturn

Who is Piyush Pratik, the IIT-graduate Apple product manager who spoke about Camera Control feature on iPhone 16 series

Apple introduced its iPhone 16 series at a launch event where Piyush Pratik highlighted the new Camera Control feature. An IIT Delhi alumnus and Stanford MBA graduate, Pratik has a notable career hist...

3 months ago - The Times of India

Biocon, ABRFL, Hindustan Copper among other stocks in F&O ban list on September 9

As of today, September 9, 2024, several stocks are under a trading ban in the futures and options (F&O) markets. This ban is enforced when the open interest on a stock reaches more than 95% of the mar...

3 months ago - Business Upturn

Stocks to watch: Maruti, TVS Motors, Emami, NBCC, Biocon, Eicher Motors in focus today (Sept 2, 2024)

The Indian stock market is poised for an eventful day as several companies make headlines with significant developments. From sales figures to acquisitions and regulatory changes, here’s a quick rundo...

3 months ago - Business Upturn